ISSN: 2471-9846

Journal of Community & Public Health Nursing
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • J Comm Pub Health Nursing 6: 251,
  • DOI: 10.4172/2471-9846.1000251

COVID-19 Pandemic: Evidences from Clinical Studies

Ravi Shankar Singh1, Abhishek Kumar Singh2, Kamla Kant Shukla3 and Amit Kumar Tripathi4*
1Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada
2Amity Institute of Neuropsychology and Neurosciences, Amity University, Uttar Pradesh, Noida, India
3Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, India
4Department of Internal Medicine, University of Iowa, Iowa City, IA, USA
*Corresponding Author : Amit Kumar Tripathi, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA, Email: amitibt2008@gmail.com

Received Date: Sep 09, 2020 / Accepted Date: Sep 14, 2020 / Published Date: Sep 21, 2020

Abstract

The public health crisis is started with emergence of new coronavirus on 11 February 2020 which triggered as coronavirus disease-2019 (COVID-19) pandemics. The causative agent in COVID-19 is made up of positively wrapped single-stranded RNA viruses ~ 30 kb in size. The epidemiology, clinical features, pathophysiology, and mode of transmission have been documented well in many studies, with additional clinical trials are running for several antiviral agents. The spreading potential of COVID-19 is faster than its two previous families, the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV). Apart from clinical manifestation, comorbid status is playing key role for prevalence of COVID-19 infection and mortalities. The comorbid effects associated with COVID-19 are diabetes, cardiovascular, digestive, hepatitis-B, cerebrovascular, hypertension, liver injury, coronary heart disease, cancer, rheumatoid arthritis, and neurological impairment. Antimalarial drugs (chloroquine and hydroxychloroquine), remdesivir, Tocilizumab, clopinavir/ritonavir, convalescent plasma therapy, spike protein-angiotensin-converting enzyme 2 (ACE2) inhibitors, human monoclonal antibodies, mRNA-1273, mesenchymal stem cells, Indian and Chinese traditional medicine, small molecules antioxidant, natural products and dietary supplements, high doses of vitamin-E, -C, -D, minerals, flavonoids,and IFN-beta are therapeutic intervention running to develop treatment against COVID-19. Although clinical usage of these therapeutic agents against COVID-19 is well documented, cytokine storms, absence of appropriate animal model have limited its therapeutic use. This review explores the clinical information currently available on COVID-19 on the mechanisms of infection, prevention, management, comorbid status, and current drug treatment options.

Keywords: COVID-19; SARS-CV-2; Comorbid condition; Antimalarial drugs; Remdesivir

Citation: Singh RS, Singh AK, Shukla KK, Tripathi AK (2020) COVID-19 Pandemic: Evidences from Clinical Studies. J Comm Pub Health Nursing 6: 251. Doi: 10.4172/2471-9846.1000251

Copyright: © 2020 Singh RS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top